Trials / Withdrawn
WithdrawnNCT03920839
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
A Phase 1b Combination Study of INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose of INCMGA00012 in combination with common standard-of-care chemotherapy regimens in participants with advanced solid tumors.
Conditions
- Advanced and/or Metastatic Solid Tumors
- Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer
- Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Retifanlimab | INCMGA00012 administered intravenously every 3 weeks. |
| DRUG | Gemcitabine | Gemcitabine administered intravenously on Days 1 and 8 of 21-day cycles. |
| DRUG | Cisplatin | Cisplatin administered intravenously on Day 1 of 21-day cycles. |
| DRUG | Pemetrexed | Pemetrexed administered intravenously on Day 1 of 21-day cycles. |
| DRUG | Carboplatin | Carboplatin AUC5 or AUC6 administered intravenously on Day 1 of 21-day cycles. |
| DRUG | Paclitaxel | Paclitaxel administered intravenously on Day 1 of 21-day cycles. |
Timeline
- Start date
- 2019-07-15
- Primary completion
- 2019-11-04
- Completion
- 2019-11-04
- First posted
- 2019-04-19
- Last updated
- 2020-04-24
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03920839. Inclusion in this directory is not an endorsement.